NCT04508530 - Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

August 27, 2024

Study Completion Date

October 30, 2024

Conditions

Pediatric Acute-Onset Neuropsychiatric Syndrome

Interventions

BIOLOGICAL

Panzyga

Panzyga 10% IVIG

OTHER

Placebo

Trial Locations (12)

Octapharma Research Site, Genova

Octapharma Research Site, Stockholm

Octapharma Research Site, Gothenburg

Octapharma Research Site, Little Rock

Octapharma Research Site, Centennial

Octapharma Research Site, Tucson

Octapharma Research Site, Los Angeles

Octapharma Research Site, Palo Alto

Octapharma Research Site, Boston

Octapharma Research Site, Lebanon

Octapharma Research Site, Roma

Octapharma Research Site, Roma